Biotech firm to use Merck’s CRISPR patents in rodent models

13-12-2018

Biotech firm to use Merck’s CRISPR patents in rodent models

France-based biotechnology company genOway has acquired the exclusive global rights to German pharmaceutical company Merck Group’s CRISPR patents, to be used in the production and sale of rodent models.


Merck Group, genOway, licensing agreement, CRISPR/Cas9, genome editing, drug delivery, proprietary technology, research, genetically modified mice, rats

More on this story

Merck signs DNA licensing deal with Vertex
28-01-2019

LSIPR